SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001193125-23-302246
Filing Date
2023-12-22
Accepted
2023-12-22 17:28:29
Documents
13
Period of Report
2023-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A d719794d8ka.htm   iXBRL 8-K/A 36231
2 EX-4.1 d719794dex41.htm EX-4.1 62181
  Complete submission text file 0001193125-23-302246.txt   251092

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA annx-20231220.xsd EX-101.SCH 2848
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20231220_lab.xml EX-101.LAB 19465
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20231220_pre.xml EX-101.PRE 12143
7 EXTRACTED XBRL INSTANCE DOCUMENT d719794d8ka_htm.xml XML 4035
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

IRS No.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39402 | Film No.: 231510912
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)